Ulcerative Colitis

Several factors that impaired healing included former smoking and seton insertion.

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.

In total, 64.9% of patients who achieved clinical response with ustekinumab during induction were in symptomatic remission after 44 weeks.

Recent qualitative studies found social isolation in patients with IBD is 1 of the main obstacles to leading a normal life.

The FDA approved risankizumab for patients with Crohn's disease in June.

The genus most consistently associated with Crohn’s disease was Fusobacterium, but disease-associated genera were mostly inconsistent between studies.

Patients with IBD were approximately 3.5 times more likely to have moderate or severe periodontitis.

Drs. Maia Kayal and David P. Hudesman discuss their hopes and future directions in the treatment of patients with ulcerative colitis.

Experts in gastroenterology share the clinical trial end points and metrics they use to guide their treatment of patients with ulcerative colitis.

The increase in EoE incidence was most pronounced in men and for patients aged 40 years and older.

There has been a significant increase of IBD overall and Crohn’s disease specifically in pediatric patients between 2000-2014.

There was a 25% relative reduction and a 0.3% absolute reduction in prevalence-adjusted index surgery rates for Crohn’s disease between 2007-2016.

Malnutrition rates were similar between patients with ulcerative colitis and patients with Crohn’s disease.

Maia Kayal, MD, explains how treatment guidelines can be used to direct and standardize treatment approaches in patients with ulcerative colitis.

Maia Kayal, MD, and David P. Hudesman, MD, discuss the importance of efficacy and safety data in the management of patients with ulcerative colitis and how this impacts treatment choice.

There were 248 patients included in the study with genetic data, with no differences found in mean titer after 2 or 3 doses between carriers and non-carriers of HLA-A24 associated with severe disease during COVID-19 infections.

Mesalamine use was linked to fewer relapses in the ulcerative colitis or IBD-unclassified cohorts compared to patients with Crohn’s disease.

Experts in gastroenterology provide an overview of induction vs maintenance therapy options, and comment on how their approach to treatment differs in patients with disease remission.

Maia Kayal, MD, and David P. Hudesman, MD, review their approaches to treatment in patients with ulcerative colitis.

Clinical remission at week 4 and the steroid dose reduction rate at week 4 were linked to medication discontinuation within 12 weeks.

Drs Maia Kayal and David P. Hudesman provide an overview of the treatment landscape for the management of ulcerative colitis, highlighting efficacy and safety considerations.

Endoscopic subscores can determine whether a patient is a suitable candidate for dose reduction.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.